Study: Upfront Atezolizumab/Nab-Paclitaxel Treatment for TNCB Reduces Risk of Disease Progression – APhA submits compounding comments to FDA.

16321_pharmacyboard_standard_080416Alabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Study: Upfront Atezolizumab/Nab-Paclitaxel Treatment for TNCB Reduces Risk of Disease Progression – APhA submits compounding comments to FDA. – (866) 348-2889.

Upfront treatment with atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) significantly reduced the risk of disease progression or death compared with nab-paclitaxel alone in patients with metastatic or unresectable locally advanced triple-negative breast cancer (TNBC), according to topline results from the phase III IMpassion130 study.

Genentech (Roche), the manufacturer of the PD-L1 inhibitor, also noted in a press release that, “Overall survival (OS) is encouraging in the PD-L1–positive population at this interim analysis, and follow-up will continue until the next planned analysis.” The company also reported that no new safety signals emerged with the combination and adverse events (AEs) were consistent with previous single-agent use of the drugs.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.